Investment group Ambient Sound Investments (ASI) has agreed to invest 1.6 million euros in Estonian biotechnology drug developer Celecure to accelerate the international breakthrough of its projects.
Swedish company Angitia AB and Estonian company Celecure AS sign a worldwide licensing agreement for a novel angiogenesis inhibitor for treatment of cancer.